April 3, 2026
Experts discuss managing zolbetuximab side effects and sequencing therapies for advanced gastroesophageal cancers based on complex biomarker profiles.
April 2, 2026
Experts discuss the evolving, multidisciplinary management of CSCC & BCC, highlighting immunotherapy's role in neoadjuvant and adjuvant settings.
April 1, 2026
Dr. Hanny Al-Samkari discusses complex ITP cases from ASH 2025, covering new agents, ICI-ITP, and patient-specific treatment strategies.
March 30, 2026
AKT inhibition with capivasertib improves progression-free survival in PTEN-deficient prostate cancer, with manageable, on-target side effects.
March 28, 2026
Experts discuss managing hyperglycemia from PI3K/AKT inhibitors in breast cancer, covering monitoring, metformin, and multidisciplinary care.
March 26, 2026
Experts discuss the shift to neoadjuvant immunotherapy for MSI-high colorectal cancer, debating response assessment, duration, and ctDNA's role.
March 25, 2026
Experts discuss novel therapies for bladder cancer: PD-1 inhibitors for NMIBC, EVP for MIBC, and the rising role of ctDNA to guide treatment.
March 24, 2026
Experts discuss zanidatumab's practice-changing potential in advanced gastroesophageal cancer, debating patient selection and toxicity management.
March 23, 2026
Dr. Paul Richardson discusses CELMoDs for multiple myeloma: a potent oral class overcoming resistance with a distinct mechanism and safety profile.
March 21, 2026
Dr. Hanny Al-Samkari reviews complex ITP cases, favoring early TPORA use over repeated steroids and deferring splenectomy for newer agents.
March 19, 2026
Experts discuss managing HER2+ GI cancers, debating TIGIT inhibitors, sequencing therapies, the need for re-biopsy, and new targeted agents.
March 18, 2026
Dr. Lajos Pusztai explores ctDNA's role in breast cancer, from detecting molecular relapse before clinical recurrence to guiding therapy.
March 16, 2026
Dr. Ravin Ratan discusses desmoid tumor management, highlighting nirogacestat, voreloxastat, and the shift from surgery to systemic therapies.
March 14, 2026
Experts discuss nuanced treatment strategies for complex HER2-positive GI cancers, weighing targeted therapies in challenging patient cases.
March 13, 2026
Dr. Bijal Shah details the evolution of CD19xCD3 BiTEs for ALL, from blinatumomab's frontline success to promising next-gen bispecifics.
March 12, 2026
Next-gen CD19 BiTEs are revolutionizing adult ALL treatment, overcoming prior therapy failures with superior efficacy and improved safety profiles.
March 10, 2026
ASH 2025 CLL highlights: Key trials show frontline options are equivalent at 3 years, with new data on next-gen BTKis and CAR-T therapy.
March 9, 2026
Experts discuss novel ITP treatments like unalumab and riluzobrutinib from ASH 2025, heralding a new era beyond corticosteroids.
March 7, 2026
Ovarian cancer treatment is transforming with new ADCs, IO therapy, and novel agents, shifting focus to biomarkers and strategic sequencing.
March 6, 2026
A new wave of agents, led by Antibody-Drug Conjugates (ADCs), immunotherapy, and cell cycle regulators, is transforming ovarian cancer treatment.
Ovarian cancer care evolves with targeted PARP inhibitors and new ADCs like mirvetuximab, shifting the paradigm towards biomarker-driven therapy.
Dr. Chris Lieu discusses ctDNA analysis in colorectal cancer, a powerful prognostic tool guiding adjuvant chemotherapy and personalizing patient care.
March 3, 2026
ASH 2025 ITP Review: Dr. Al-Samkari discusses a new treatment era with yanalumab (VEHIT-2) and rilzabrutinib (LUNA-3), detailing efficacy.
March 2, 2026
Experts review new ADC data for breast cancer, detailing T-DXd's role in HER2+ disease and comparing Trop-2 ADCs for TNBC and ER+ settings.
February 18, 2026
Experts discuss next-gen CELMoDs in multiple myeloma, detailing their potent mechanism, trial data, and role in high-risk & extramedullary disease.
February 17, 2026
Experts discuss EV+pembro for metastatic bladder cancer, covering toxicity management, durable responses, and sequencing targeted therapies.
February 16, 2026
ESMO 2025 GYN cancer highlights: IO shows promise in platinum-resistant ovarian cancer, new ADCs emerge, and biomarker-driven therapy expands.
February 13, 2026
ASH 2025 myeloma review: Tekdara shows major survival benefit, belantamab's ocular toxicity is manageable, and BCL-2 inhibitors are promising.
February 12, 2026
Dr. Marwan Fakih discusses squamous cell carcinoma of the anal canal (SCAC), highlighting IO+chemo's impact and the potential for cure.
February 11, 2026
The PODIUM-303 trial establishes a new standard for advanced anal cancer: adding retifenlimab to chemo improves PFS, ORR, and overall survival.
February 10, 2026
ESMO 2025 prostate cancer update: The Embark trial's striking OS benefit sets a new standard, while PARP inhibitors show promise for earlier use.
February 9, 2026
Dr. Kathleen Moore discusses transformative ADCs in ovarian cancer, detailing their efficacy, unique toxicities like ILD, and future challenges.
ADCs are revolutionizing ovarian cancer treatment. Dr. Kathleen Moore discusses key targets (FRα, TROP2), new agents, and future challenges.
February 7, 2026
Experts discuss new paradigms in localized CRC: neoadjuvant IO for MSI-H, FOLFOX+atezo post-op, and ctDNA's role in guiding therapy.
February 6, 2026
Experts review ITP management from ASH 2025, covering TPO agonists, BTK inhibitors, and the promising new agent yanalumab.
February 5, 2026
ESMO 2025 bladder cancer updates: EVP shows major survival benefit in MIBC, durvalumab improves NMIBC outcomes, and ctDNA guides adjuvant IO.
February 3, 2026
ASH 2025 myeloma review: In vivo CAR-T shows promise, belantamab dosing gets flexible, siltacel data suggests cure, & new combos tackle tough cases.
February 2, 2026
Experts review pivotal data for zanidatumab (HER2) & zolbituximab (Claudin 18.2) in advanced gastroesophageal cancer management.
January 28, 2026
Experts discuss new HER2-targeted therapies like zanidatumab & TDXD for biliary, gastric, & colorectal cancers, covering new data & cases.
January 27, 2026
Experts review optimal endocrine strategies for ER+ breast cancer, from genomic assays and CDK4/6i to new PI3K inhibitors and oral SERDs.
January 21, 2026
ASH 2025 review: Bispecific antibodies show durable responses and are moving to frontline lymphoma therapy with new combinations setting standards.
January 14, 2026
Experts debate new HER2+ breast cancer data, covering TDXD's role in neoadjuvant/1st-line settings, brain met management, and toxicity protocols.
Experts review ADCs (polatuzumab) and bispecifics in DLBCL & FL, debating sequencing, toxicity management, and their role vs. CAR-T therapy.
January 12, 2026
Circulating tumor DNA (ctDNA) is transforming colorectal cancer care, guiding adjuvant therapy, predicting benefit, and shaping future MRD trials.
January 10, 2026
Experts discuss managing myelofibrosis with tailored JAK inhibitors and novel agents, plus the complex diagnosis and treatment of systemic mastocytosis.
January 8, 2026
Experts discuss new ADC trial data for metastatic breast cancer, covering sacituzumab, TDXD, and datopotamab, and debating sequencing strategies.
January 7, 2026
Experts discuss the shift to targeted therapies in CLL, comparing BTKi and venetoclax, managing AEs, and sequencing for relapsed disease.
January 6, 2026
Tumor-informed ctDNA assays are transforming colorectal cancer care, enabling precise risk stratification and guiding adjuvant therapy decisions.
January 3, 2026
Experts discuss the future of AML management, focusing on fitness-based therapy, targeted agents for FLT3/IDH, and new menin inhibitors.
